市場調査レポート

製薬会社上位25社のパイプライン分析と売上高予測

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023

発行 Kalorama Information 商品コード 299928
出版日 ページ情報 英文 400 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
製薬会社上位25社のパイプライン分析と売上高予測 Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023
出版日: 2014年04月07日 ページ情報: 英文 400 Pages
概要

世界の医薬品市場では、近年数多くの重大な変化が起きており、そのなかには、市場の成長を妨げる方向に作用するものがある一方、新たなビジネスチャンスをもたらすようなものもあります。製薬業界は、人口の高齢化、傷病率の上昇、未対応の医療ニーズ、各国政府の動きなどマクロ経済面のさまざまな要因の影響を受けています。また、多くのブロックバスター製品が特許の期限切れを迎え、ジェネリック医薬品との競争に晒されるようになったことで、市場の様相は大きく変化しています。さらに、バイオテクノロジー開発への関心が高まったことで、これまで化学薬品が中心だった製薬業界の関心が生物学的治療にも向かうようになり、これが医療のさまざまな領域での大きな変化へとつながっています。

当レポートは、世界の製薬会社上位25社に注目し、各社の業績を分析するとともに、2023年までの売上高を予測したもので、売上高、研究開発支出、売上高の地域別内訳、個々の製品や各部門の業績、パイプラインの後期開発段階にある製品、成長戦略などの情報を盛り込み、概略下記の構成でお届けします。

エグゼクティブサマリー

  • イントロダクション
  • 調査範囲と方法
  • 将来的な市場機会
  • 主な企業

イントロダクション

  • 世界の医薬品市場
  • 製薬業界上位25社の概要
  • 世界の医療支出
  • 高齢化の進行と医薬品市場への影響

医薬品研究開発のトレンド

  • 医薬品研究開発の概要
  • 承認率
  • より良い標的の選定
  • 研究開発支出の多い企業
  • パイプラインの概要
  • 広がる疾病治療の選択肢
  • バイオテクノロジーを利用した医薬品開発
  • 希少疾病用医薬品(オーファンドラッグ)
  • ファストトラック指定の医薬品
  • 医薬品承認の迅速化を目的とした各種の制度
  • 画期的な治療
  • 医薬品規制が認める独占権
  • 小児用医薬品の特許保護期間延長
  • 製薬業界のバイオシミラー(バイオジェネリック)開発と独占権
  • 法整備
  • バイオシミラー開発の複雑さ
  • バイオシミラーに対する米国の排他性
  • 日本と中国のバイオシミラー
  • 欧州のバイオシミラー
  • 企業戦略:合併、買収、協力
  • 受託研究機関の役割

SANOFI

GLAXOSMITHKLINE PLC

JOHNSON & JOHNSON

ASTRAZENECA PLC

PFIZER, INC

NOVARTIS AG

ROCHE LTD.

MERCK & CO., INC

ELI LILLY AND COMPANY

ABBVIE, INC.

TEVA PHARMACEUTICAL INDUSTRIES, LTD.

AMGEN, INC.

BRISTOL-MYERS SQUIBB COMPANY

武田薬品工業

BAYER AG

NOVO NORDISK

大塚製薬

MERCK KGAA

ACTAVIS

MYLAN

BOEHRINGER INGELHEIM GMBH

第一三共

アステラス

GILEAD SCIENCES

BAXTER INTERNATIONAL

市場のサマリーと予測分析

  • 概要
  • 市場のトレンドと各分野の売上高
  • 心血管/血液
  • 神経治療
  • 感染症治療
  • 腫瘍
  • 呼吸器と炎症
  • 他の市場
  • 2013年に市場で起きた変化の評価
  • 対前年比成長率の分析
  • 企業分析
  • 市場予測
  • 各社の今後の展望
  • 変わり行く製薬業界での持続可能性
  • 結論

図表

目次
Product Code: KLI5225671

Kalorama Information's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides:

  • Revenues
  • R&D Spending 2007-2013
  • Geographic Breakout of Revenues
  • Performance of Specific Products
  • Performance by Drug Category
  • Late-Stage Pipeline
  • Projections of Revenues to 2023

In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades.

The companies included in the study are:

  • Pfizer, inc.
  • Novartis AG
  • Roche ltd.
  • Merck & Co., inc.
  • Sanofi
  • Glaxosmithkline PLC
  • Johnson & johnson
  • Astra Zeneca plc
  • Eli Lilly and Company
  • Abbvie, inc.
  • Teva Pharmaceutical Industries, Ltd.
  • Amgen, inc.
  • Bristol-myers Squibb Company
  • Takeda Pharmaceutical co., LTD
  • Bayer AG
  • Novo nordisk
  • Boehringer Ingelheim gmbh
  • Daiichi Sankyo
  • Astellas
  • Gilead Sciences
  • Otsuka Pharmaceutical
  • Merck KGAA
  • Actavis
  • Mylan
  • Baxter international

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals; diagnostics; devices; chemicals; agriculture; and animal health. Strategic acquisitions and partnerships with biotech companies have allowed traditional pharmaceutical companies an opportunity to become diverse in pipelines and product offerings. Companies like Amgen, which specialize in biotechnology, now compete with a growing number of what the industry has once considered to be the traditional pharmaceutical company, This is a trend expected to continue to grow as interest in the small biotechnology focused companies continue to be acquired by the Pfizer's, Novartis' and Roche's of the industry

Table of Contents

EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Future Market Opportunity
  • Leading Companies

INTRODUCTION

  • Global Pharmaceutical Market
  • Top 25 Pharmaceutical Companies: An Overview
  • Global Healthcare Spending
  • Aging Population and Impact on Pharmaceutical Markets

TRENDS IN PHARMACEUTICAL RESEARCH AND DEVELOPMENT

  • Pharmaceutical Research & Development Overview
  • Percent of Approvals
  • Selecting Better Targets
  • Top R&D Spenders
  • The Pipeline Snapshot
  • Expanded Options in Treating Diseases
  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Breakthrough Therapy
  • Pharmaceutical Regulatory Exclusivity
  • Pediatric Extensions
  • Pharmaceutical Industry-Biosimilar (Biogeneric) Development and Exclusivity
  • Legislation
  • Complications with Biosimilar Development
  • U.S. Exclusivity for Biosimilars
  • Biosimilars in Japan and China
  • Biosimilars in Europe
  • Corporate Strategy: Mergers, Acquisitions, and Collaborations
  • The Role of Contract Research Organizations

SANOFI

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

GLAXOSMITHKLINE PLC

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

JOHNSON & JOHNSON

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

ASTRAZENECA PLC

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

PFIZER, INC

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

NOVARTIS AG

  • Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

ROCHE LTD.

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

MERCK & CO., INC

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

ELI LILLY AND COMPANY

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

ABBVIE, INC.

  • Overview
  • Financial Performance and Investments
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TEVA PHARMACEUTICAL INDUSTRIES, LTD.

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

AMGEN, INC.

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

BRISTOL-MYERS SQUIBB COMPANY

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TAKEDA PHARMACEUTICAL CO., LTD.

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

BAYER AG

  • Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

NOVO NORDISK

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

OTSUKA PHARMACEUTICAL

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

MERCK KGAA

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

ACTAVIS

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Late Stage Pipeline
  • Growth Strategy

MYLAN

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Pipeline
  • Growth Strategy

BOEHRINGER INGELHEIM GMBH

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

DAIICHI SANKYO

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

ASTELLAS

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

GILEAD SCIENCES

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

BAXTER INTERNATIONAL

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Pipeline
  • Growth Strategy

MARKET SUMMARY AND FORECAST ANALYSIS

  • Overview
  • Market Trends and Values by Therapeutic Area
  • Cardiovascular/Blood Market Analysis
  • Neurotherapeutics Market Analysis
  • Infection Treatments Market Analysis
  • Oncology Market Analysis
  • Respiratory and Inflammation Market Analysis
  • Other Drug Market Analysis
  • Evaluating Changes in 2013 Market Value
  • Year-over-Year Growth Analysis
  • Company Analysis
  • Market Forecast
  • Future Company Outlook
  • Sustainability in a Changing Pharmaceutical Industry
  • Conclusions

TABLE OF EXHIBITS

EXECUTIVE SUMMARY

  • Figure 1-1 Global Pharmaceutical Market, 2011-2013 and Forecasted 2023
  • Table 1-2 Global Pharmaceutical Market Forecast by Therapeutic Segment, 2023-based on late stage development projects evaluated

INTRODUCTION

  • Figure 2-1 Global Pharmaceutical Market by Therapeutic Area, 2011-2013 and Forecasted 2023
  • Table 2- 1 Top Pharmaceutical Companies, 1-25 by 2013 Pharmaceutical Sales
  • Figure 2-2 Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales 2013
  • Table 2-2 Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2012
  • Figure 2-3 Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2012
  • Table 2-3 International Population Trend Age 65+ International Population Trend Age 65+
  • Table 2-4 United States Population Trend Age 65+ United States Population Trend Age 65+

TRENDS IN PHARMACEUTICAL RESEARCH AND DEVELOPMENT

  • Table 3-1 Phases of Clinical Drug Development
  • Table3-2 Top R&D Spenders in the Pharmaceutical Industry2011, 2012 and 2013
  • Figure 3-1 Top 10 R&D Spenders in the Pharmaceutical Industry, 2013 Comparison by Company24
  • Table 3-3 Company Pipelines by Total Late Stage Development Projects by General Therapeutic Segment (Top 25 Companies by Revenues)
  • Figure 3-2 Company Pipelines by Total Late Stage Development Projects
  • Figure 3-3 Company Pipelines, Leaders by Therapeutic Area
  • Table 3-4 Orphan Drug Designations Granted and Approved by the FDA 1983-2013

PFIZER, INC

  • Table 4-1 Pfizer Corporate Summary
  • Table 4-2 Pfizer: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 4-1 Pfizer: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 4-2 Pfizer: Break-up of Total Revenues by Region, 2013
  • Figure 4-3 Pfizer: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 4-4 Pfizer: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 4-3 Pfizer: Leading Pharmaceutical Products, 2013 Sales
  • Table 4-4 Pfizer: Late Stage Product Pipeline
  • Table 4-4 (continued) Pfizer: Late Stage Product Pipeline
  • Figure 4-5 Pfizer: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 4-5 Highlighted Corporate Developments

NOVARTIS AG

  • Table 5-1 Novartis Corporate Summary
  • Table 5-2 Novartis: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 5-2 Novartis: Break-up of Sales by Region, 2013
  • Figure 5-3 Novartis: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 5-4 Novartis: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 .. 83
  • Table 5-3 Novartis: Leading Pharmaceutical Products, 2013 Sales
  • Table 5-4 Novartis: Late Stage Product Pipeline
  • Table 5-4 (continued) Novartis: Late Stage Product Pipeline
  • Table 5-4 (continued) Novartis: Late Stage Product Pipeline
  • Table 5-4 (continued) Novartis: Late Stage Product Pipeline
  • Figure 5-5 Novartis: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 5-5 Highlighted Corporate Developments

ROCHE LTD.

  • Table 6-1 Roche Corporate Summary
  • Table 6-2 Roche: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 6-2 Roche: Break-up of Sales by Region, 2013
  • Figure 6-3 Roche: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 6-4 Roche: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 6-3 Roche: Leading Pharmaceutical Products, 2013 Sales
  • Table 6-4 Roche: Late Stage Product Pipeline
  • Table 6-4 (continued) Roche: Late Stage Product Pipeline
  • Table 6-4 (continued) Roche: Late Stage Product Pipeline
  • Figure 6-5 Roche: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 6-5 Highlighted Corporate Developments

MERCK & CO., INC

  • Table 7-1 Merck Corporate Summary
  • Table 7-2 Merck: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 7-2 Merck: Break-up of Sales by Region, 2013
  • Figure 7-3 Merck: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 7-4 Merck: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 7-3 Merck: Leading Pharmaceutical Products, 2013 Sales
  • Table 7-4 Merck: Late Stage Product Pipeline
  • Table 7-4 (continued) Merck: Late Stage Product Pipeline
  • Figure 7-5 Merck: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 7-5 Highlighted Corporate Developments

SANOFI

  • Table 8-1 Sanofi Corporate Summary
  • Table 8-2 Sanofi: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 8-2 Sanofi: Break-up of Sales by Region, 2013
  • Figure 8-3 Sanofi: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 8-4 Sanofi: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 8-3 Sanofi: Leading Pharmaceutical Products, 2013 Sales
  • Table 8-4 Sanofi Late Stage Product Pipeline
  • Table 8-4 (continued) Sanofi Late Stage Product Pipeline
  • Figure 8-5 Sanofi: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 8-5 Highlighted Corporate Developments

GLAXOSMITHKLINE PLC

  • Table 9-1 GlaxoSmithKline Corporate Summary
  • Table 9-2 GlaxoSmithKline: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 9-2 GlaxoSmithKline: Break-up of Sales by Region, 2013
  • Figure 9-3 GlaxoSmithKline: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 9-4 GlaxoSmithKline: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 9-3 GlaxoSmithKline: Leading Pharmaceutical Products, 2013 Sales
  • Table 9-4 GlaxoSmithKline: Late Stage Product Pipeline
  • Table 9-4 (continued) GlaxoSmithKline: Late Stage Product Pipeline
  • Table 9-4 (continued) GlaxoSmithKline: Late Stage Product Pipeline
  • Figure 9-5 GlaxoSmithKline: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 9-5 Highlighted Corporate Developments

JOHNSON & JOHNSON

  • Table 10-1 Johnson & Johnson Corporate Summary
  • Table 10-2 Johnson & Johnson: Total Company Revenue and Total R&D Spending 2007-2013 . 149
  • Figure 10-2 Johnson & Johnson: Break-up of Sales by Region, 2013
  • Figure 10-3 Johnson & Johnson: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 10-4 Johnson & Johnson: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 10-3 Johnson & Johnson: Leading Pharmaceutical Products, 2013 Sales
  • Table 10-4 Johnson & Johnson: Late Stage Product Pipeline
  • Table 10-4 (continued) Johnson & Johnson: Late Stage Product Pipeline
  • Figure 10-5 Johnson & Johnson: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 10-5 Highlighted Corporate Developments

ASTRAZENECA PLC

  • Table 11-1 AstraZeneca Corporate Summary
  • Table 11-2 AstraZeneca: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 11-2 AstraZeneca: Break-up of Sales by Region, 2013
  • Figure 11-3 AstraZeneca: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023164
  • Figure 11-4 AstraZeneca: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 11-3 AstraZeneca: Leading Pharmaceutical Products, 2013 Sales
  • Table 10-4 AstraZeneca: Late Stage Product Pipeline
  • Table 10-4 (continued) AstraZeneca: Late Stage Product Pipeline
  • Table 10-4 (continued) AstraZeneca: Late Stage Product Pipeline
  • Figure 11-5 AstraZeneca: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 10-5 Highlighted Corporate Developments

ELI LILLY AND COMPANY

  • Table 12-1 Eli Lilly Corporate Summary
  • Table 12-2 Eli Lilly's Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 12-2 Eli Lilly & Co.: Break-up of Sales by Region, 2013
  • Figure 12-3 Eli Lilly & Co.: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023180
  • Figure 12-4 Eli Lilly & Co.: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 12-3 Eli Lilly & Co.: Leading Pharmaceutical Products, 2013 Sales
  • Table 12-4 Eli Lilly: Late Stage Product Pipeline
  • Figure 12-5 Eli Lilly & Co.: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 12-5 Highlighted Corporate Developments

ABBVIE, INC.

  • Table 13-1 AbbVie Corporate Summary
  • Table 13-2 AbbVie: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 13-2 AbbVie: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 13-3 AbbVie: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 . 191
  • Table 13-3 AbbVie: Leading Pharmaceutical Products, 2013 Sales
  • Table 13-4 AbbVie: Late Stage Product Pipeline
  • Figure 13-5 AbbVie: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 13-5 Highlighted Corporate Developments

TEVA PHARMACEUTICAL INDUSTRIES, LTD.

  • Table 14-1 Teva Pharmaceutical Corporate Summary
  • Table 14-2 Teva Pharmaceutical: Total Company Revenue and Total R&D Spending 2007-2013198
  • Figure 14-2 Teva Pharmaceutical: Break-up of Sales by Region, 2013
  • Figure 14-3 Teva Pharmaceutical: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 14-4 Teva Pharmaceutical: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 14-3 Teva Pharmaceutical: Leading Pharmaceutical Products, 2013 Sales
  • Table 14-4 Teva Pharmaceutical: Late Stage Product PipelineBrand Development
  • Table 14-4 (continued) Teva Pharmaceutical: Late Stage Product PipelineBrand Development
  • Figure 14-5 Teva Pharmaceutical: Late Stage Product Pipeline by Therapeutic Area (Brand Therapeutics)Comparing 2009, 2011 and 2013
  • Table 14-5 Highlighted Corporate Developments

AMGEN, INC.

  • Table 15-1 Amgen Corporate Summary
  • Table 15-2 Amgen: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 15-2 Amgen: Break-up of Sales by Region, 2013
  • Figure 15-3 Amgen: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 15-4 Amgen: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 15-3 Amgen: Leading Pharmaceutical Products, 2013 Sales
  • Table 15-4 Amgen: Late Stage Product Pipeline
  • Table 15-4 (continued) Amgen: Late Stage Product Pipeline
  • Figure 15-5 Amgen: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 15-5 Highlighted Corporate Developments

BRISTOL-MYERS SQUIBB COMPANY

  • Table 16-1 Bristol-Myers Squibb Corporate Summary
  • Table 16-2 Bristol-Myers Squibb's Total Company Revenue and Total R&D Spending 2007-2013223
  • Figure 16-2 Bristol-Myers Squibb: Break-up of Sales by Region, 2013
  • Figure 16-3 Bristol-Myers Squibb: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 16-4 Bristol-Myers Squibb: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 16-3 Bristol-Myers Squibb: Leading Pharmaceutical Products, 2013 Sales
  • Table 16-4 Bristol-Myers Squibb: Late Stage Product Pipeline
  • Table 16-4 (continued) Bristol-Myers Squibb: Late Stage Product Pipeline
  • Figure 16-5 Bristol-Myers Squibb: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 16-5 Highlighted Corporate Developments

TAKEDA PHARMACEUTICAL CO., LTD.

  • Table 17-1 Takeda Corporate Summary
  • Table 17-2 Takeda's Total Company Revenue* and Total R&D Spending 2007-2013
  • Figure 17-2 Takeda: Break-up of Sales by Region, 2013
  • Figure 17-3 Takeda: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 17-4 Takeda: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 .. 241
  • Table 17-3 Takeda: Leading Pharmaceutical Products, 2013 Sales
  • Table 17-4 Takeda Pharmaceutical: Late Stage Product Pipeline
  • Table 17-4 (continued) Takeda Pharmaceutical: Late Stage Product Pipeline
  • Figure 17-5 Takeda: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 17-5 Highlighted Corporate Developments

BAYER AG

  • Table 18-1 Bayer Corporate Summary
  • Table 18-2 Bayer's Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 18-2 Bayer: Break-up of Sales by Region, 2013
  • Figure 18-3 Bayer: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 18-4 Bayer: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 18-3 Bayer: Leading Pharmaceutical Products, 2013 Sales
  • Table 18-4 Bayer: Late Stage Product Pipeline
  • Table 18-4 (continued) Bayer: Late Stage Product Pipeline
  • Figure 18-5 Bayer: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 18-5 Highlighted Corporate Developments

NOVO NORDISK

  • Table 19-1 Novo Nordisk Corporate Summary
  • Table 19-2 Novo Nordisk: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 19-2 Novo Nordisk: Break-up of Sales by Region, 2013
  • Figure 19-3 Novo Nordisk: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023267
  • Figure 19-4 Novo Nordisk: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 19-3 Novo Nordisk: Leading Pharmaceutical Products, 2013 Sales
  • Table 19-4 Novo Nordisk: Late Stage Product Pipeline
  • Figure 19-5 Novo Nordisk: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 19-5 Highlighted Corporate Developments

BOEHRINGER INGELHEIM GMBH

  • Table 20-1 Boehringer Ingelheim Corporate Summary
  • Table 20-2 Boehringer Ingelheim: Total Company Revenue and Total R&D Spending 2007-2013275
  • Figure 20-2 Boehringer Ingelheim: Break-up of Sales by Region, 2013
  • Figure 20-3 Boehringer Ingelheim: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 20-4 Boehringer Ingelheim: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 20-3 Boehringer Ingelheim: Leading Pharmaceutical Products, 2013 Sales
  • Table 20-4 Boehringer Ingelheim: Late Stage Product Pipeline
  • Table 20-4 (continued) Boehringer Ingelheim: Late Stage Product Pipeline
  • Figure 20-5 Boehringer Ingelheim: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 20-5 Highlighted Corporate Developments

DAIICHI SANKYO

  • Table 21-1 Daiichi Sankyo Corporate Summary
  • Table 21-2 Daiichi Sankyo: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 21-2 Daiichi Sankyo: Break-up of Sales by Region, 2013
  • Figure 21-3 Daiichi Sankyo: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023291
  • Figure 21-4 Daiichi Sankyo: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 21-3 Daiichi Sankyo: Leading Pharmaceutical Products, 2013 Sales
  • Table 21-4 Daiichi Sankyo: Late Stage Product Pipeline
  • Figure 21-5 Daiichi Sankyo: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 21-5 Highlighted Corporate Developments

ASTELLAS

  • Table 22-1 Astellas Corporate Summary
  • Table 22-2 Astellas: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 22-2 Astellas: Break-up of Sales by Region, 2013
  • Figure 22-3 Astellas: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 22-4 Astellas: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 . 305
  • Table 22-3 Astellas: Leading Pharmaceutical Products, 2013 Sales
  • Table 22-4 Astellas: Late Stage Product Pipeline
  • Table 22-4 (continued) Astellas: Late Stage Product Pipeline
  • Figure 22-5 Astellas: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 22-5 Highlighted Corporate Developments

GILEAD SCIENCES

  • Table 23-1 Gilead Corporate Summary
  • Table 23-2 Gilead Sciences: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 23-1 Gilead Sciences: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 23-2 Gilead Sciences: Break-up of Sales by Region, 2013
  • Figure 23-3 Gilead Sciences: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 23-4 Gilead Sciences: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 23-3 Gilead Sciences: Leading Pharmaceutical Products, 2013 Sales
  • Table 23-4 Gilead Sciences: Late Stage Product Pipeline
  • Figure 23-5 Gilead Sciences: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 23-5 Highlighted Corporate Developments

OTSUKA PHARMACEUTICAL

  • Table 24-1 Otsuka Corporate Summary
  • Table 24-2 Otsuka Holdings: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 24-2 Otsuka Holdings: Break-up of Sales by Region, 2013
  • Figure 24-3 Otsuka Holdings: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 24-4 Otsuka Holdings: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 24-3 Otsuka Holdings: Leading Pharmaceutical Products, 2013 Sales
  • Table 24-4 Otsuka Holdings: Late Stage Product Pipeline
  • Table 24-4 (continued) Otsuka Holdings: Late Stage Product Pipeline
  • Figure 24-5 Otsuka Holdings: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 24-5 Highlighted Corporate Developments

MERCK KGAA

  • Table 25-1 Merck KGaA Corporate Summary
  • Table 25-2 Merck KGaA: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 25-1 Merck KGaA: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 25-2 Merck KGaA: Break-up of Sales by Region, 2013
  • Figure 25-3 Merck KGaA: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023342
  • Figure 25-4 Merck KGaA: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 25-3 Merck KGaA: Leading Pharmaceutical Products, 2013 Sales
  • Table 25-4 Merck KGaA: Late Stage Product Pipeline
  • Figure 25-5 Merck KGaA: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
  • Table 25-5 Corporate Development Details

ACTAVIS

  • Table 26-1 Actavis Corporate Summary
  • Table 26-2 Actavis: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 26-1 Actavis: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 26-2 Actavis: Break-up of Sales by Region, 2013
  • Figure 26-3 Actavis: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 26-4 Actavis: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 . 354
  • Table 26-3 Actavis: Late Stage Product PipelineBrand Development
  • Figure 26-5 Actavis: Late Stage Product Pipeline by Therapeutic Area (Brand Therapeutics)Comparing 2009, 2011 and 2013
  • Table 26-4 Highlighted Corporate Developments

MYLAN

  • Table 27-1 Mylan Corporate Summary
  • Table 27-2 Mylan: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 27-1 Mylan: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 27-2 Mylan: Break-up of Sales by Region, 2013
  • Figure 27-3 Mylan: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 27-4 Mylan: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 27-3 Corporate Development Details

BAXTER INTERNATIONAL

  • Table 28-1 Baxter Corporate Summary
  • Table 28-2 Baxter: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 28-1 Baxter: Total Company Revenue and Total R&D Spending 2007-2013
  • Figure 28-2 Baxter: Break-up of Sales by Region, 2013
  • Figure 28-3 Baxter: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
  • Figure 28-4 Baxter: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
  • Table 28-3 Highlighted Corporate Developments

MARKET SUMMARY AND FORECAST ANALYSIS

  • Table 29-1 Global Pharmaceutical Market, 2011-2013 and Forecasted 2023
  • Figure 29-1 Global Pharmaceutical Market, 2011-2013 and Forecasted 2023
  • Figure 29-2 Global Pharmaceutical Market by Therapeutic Area, 2011-2013 and Forecasted 2023379
  • Figure 29-3 Top 5 Cardiovascular/Blood Therapeutic Companies, 2013 Sales
  • Figure 29-4 Top 5 Neurotherapeutic Companies, 2013 Sales
  • Figure 29-5 Top 5 Infection Treatment Companies, 2013 Sales
  • Figure 29-6 Top 5 Oncology Companies, 2013 Sales
  • Figure 29-7 Top 5 Respiratory and Inflammation Product Companies, 2013 Sales
  • Figure 29-8 Top 5 Other Drug Companies, 2013 Sales
  • Figure 29-9 Global Pharmaceutical Market % Change by Therapeutic Segment, 2012- 2013
  • Table 29-2 Top Companies by 2013 Pharmaceutical Sales Growth
  • Figure 29-10 Global Pharmaceutical Market, Sales Growth by Company, 2012- 2013
  • Table 29-3 Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales 2013 Compared to 2011
  • Figure 29-11 Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales 2013 Comparednto 2011
  • Table 29-4 Top 25 Pharmaceutical Products, by 2011 and 2013 Revenues
  • Figure 29-12 Top 25 Pharmaceutical Products, by 2011 and 2013 Revenues
  • Table 29-5 Global Pharmaceutical Market Forecast by Therapeutic Segment, 2023-based on late stage development projects evaluated
  • Figure 29-13 Global Pharmaceutical Market Forecast by Therapeutic Segment, 2023-based on late stage development projects evaluated
  • Table 29-6 Evaluating Pharmaceutical Company Growth, 2013-2023
  • Figure 29-14 Evaluating Pharmaceutical Company Growth, 2013-2023
Back to Top